(Q33678028)

28 July 2017

1 reference

title

Developments in the therapeutic applications of bisphosphonates (English)

1 reference

28 July 2017

Brown DL

1

1 reference

PubMed ID

10392318

28 July 2017

Robbins R

series ordinal

2

1 reference

28 July 2017

1 July 1999

1 reference

The Journal of Clinical Pharmacology

28 July 2017

1 reference

28 July 2017

39

1 reference

28 July 2017

7

1 reference

28 July 2017

651-660

1 reference

Structure-activity relationships of various bisphosphonates

28 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Etidronate disodium in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Glucocorticoid osteoporosis--mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Duration of response with oral clodronate in Paget's disease of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Alendronate in the treatment of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Clodronate decreases the frequency of skeletal metastases in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (APD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008272

10.1177/00912709922008272

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10392318